It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

From the makers of Zarxio

ZIEXTENZO is a long-acting filgrastim biosimilar and is prescribed to patients receiving chemotherapy at risk of infection


ZIEXTENZO is a biosimilar of Neulasta® (pegfilgrastim) that can help protect you from the risk of infection during chemotherapy.

How to inject ZIEXTENZO

Learn how to inject ZIEXTENZO

ZIEXTENZO can be self-administered or administered by a caregiver. Find instructions for both methods here.

Enroll in $0 co-pay*
ZIEXTENZO $0 Co-Pay Program

Enroll in $0 co-pay*

Eligible and commercially insured patients can enroll online.

*Eligibility Requirements: Prescription must be for an approved indication. This program is not health insurance. This program is for insured patients only; cash-paying or uninsured patients are not eligible. Patients are not eligible if prescription for ZIEXTENZO is paid, in whole or in part, by any state or federally funded programs, including but not limited to Medicare (including Part D, even in the coverage gap) or Medicaid, Medigap, VA, DOD, or TRICARE, or private indemnity plans that do not cover prescription drugs, or HMO insurance plans that reimburse the patient for the entire cost of their prescription drugs, or where prohibited by law. Co-Pay Program may apply to out-of-pocket expenses that occurred within 120 days prior to the date of the enrollment. Co-Pay Program may not be combined with any other rebate, coupon, or offer. Co-Pay Program has no cash value. Sandoz reserves the right to rescind, revoke, or amend this offer without further notice.

Reference: ZIEXTENZO Prescribing Information. Sandoz Inc. March 2021.

Neulasta is a registered trademark of Amgen Inc.